STOCK TITAN

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Aileron Therapeutics (Nasdaq: ALRN) announced that Dr. Manuel Aivado, President and CEO, will present at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, at 3:30 p.m. ET in New York. A webcast of the presentation will be available on their website and archived for 30 days. Aileron, a clinical-stage oncology company, focuses on making chemotherapy safer with their drug ALRN-6924, designed to protect healthy cells during treatment while targeting cancer cells. This innovation aims to improve the quality of life for patients with p53-mutated cancers.

Positive
  • None.
Negative
  • None.

BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation and participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29, 2022, at 3:30 p.m. ET in New York, New York.

A webcast of the presentation and fireside chat will be available under the Investors & Media section of the company's website at aileronrx.com. A replay of the webcast will be archived on the Aileron website for approximately 30 days following the presentation.

About Aileron Therapeutics
Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives. ALRN-6924, our first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy, in which we exclusively focus on treating patients with p53-mutated cancers. Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells. As a result, healthy cells are spared from chemotherapeutic destruction while chemotherapy continues to kill cancer cells. By reducing or eliminating multiple chemotherapy-induced side effects, ALRN-6924 may improve patients’ quality of life and help them better tolerate chemotherapy. Enhanced tolerability may result in fewer dose reductions or delays of chemotherapy and the potential for improved efficacy. Our vision is to bring chemoprotection to all patients with p53-mutated cancers, which represent approximately 50% of cancer patients, regardless of type of cancer or chemotherapy. Visit us at aileronrx.com to learn more.

Investor Contact:Media Contact:
Stern Investor RelationsLiz Melone
Alexander Lobo617-256-6622
alex.lobo@sternir.comlmelone@aileronrx.com

FAQ

What is the date and time of Aileron Therapeutics' presentation at the Ladenburg Thalmann Healthcare Conference?

Aileron Therapeutics' presentation will take place on September 29, 2022, at 3:30 p.m. ET.

Who is presenting for Aileron Therapeutics at the Ladenburg Thalmann 2022 Healthcare Conference?

Dr. Manuel Aivado, President and CEO of Aileron Therapeutics, will be presenting.

Where can I watch the Aileron Therapeutics conference presentation?

The presentation can be watched via webcast on Aileron Therapeutics' website under the Investors & Media section.

What is ALRN-6924 and its significance in oncology?

ALRN-6924 is a first-in-class MDM2/MDMX dual inhibitor designed to protect healthy cells during chemotherapy while targeting cancer cells, potentially improving patient quality of life.

What type of cancers does Aileron Therapeutics focus on?

Aileron focuses on treating patients with p53-mutated cancers, which represent approximately 50% of cancer patients.

Aileron Therapeutics, Inc.

NASDAQ:ALRN

ALRN Rankings

ALRN Latest News

ALRN Stock Data

49.83M
21.63M
0.65%
28.47%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
AUSTIN